The addition of nivolumab to neoadjuvant chemotherapy significantly increased pathologic complete response among certain patients with breast cancer, according to findings published in Nature Medicine ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

The Weill Family Foundation is giving $50 million to enable 4 leading research institutions to form the Weill Cancer Hub East ...

Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025 Aligned with U.S. Food and Drug Administration (“FDA”) on ...

Cutaneous melanoma, the most aggressive form of skin cancer, is characterized by its accumulation of a large number of ...

A discovery published in Nature Immunology has shed light on why the immune system is less aggressive toward self-antigens, ...

The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant Imfinzi after radical cystectomy in ...

Melanoma cells, the most aggressive form of skin cancer, produce a protein that blocks the recognition and removal of the ...

Gavin Nielsen, who was 2 years old when he was diagnosed with a rare brain cancer, met Dr. Nicholas Vitanza who is part of a ...

Adjuvant camrelizumab significantly improves event-free survival in patients with locoregionally advanced nasopharyngeal ...

Researchers say they are exploring therapeutic options to block fatty acid accumulation and immunosuppressive signals between ...

AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the ...